Abstract library

61 results for "Villa".
#1777 Tumour Size Is Not a Reliable Criterion for Resection of Patients with Non-Secreting Pancreatic Neuroendocrine Tumours: Results of an International, Multi-Centre, Operative Cohort
Introduction: Small pancreatic neuroendocrine tumours (pNETs) present a management dilemma between surveillance and resection.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Logan Mills
#2077 Linked Colour Imaging Increases the Diagnostic Yield of Type 1 Gastric Carcinoids
Introduction: Type 1 Gastric carcinoid tumours (GCTs) are the most common neuroendocrine tumours of the stomach. Endoscopic diagnosis of Type 1 GCTs remains a challenge. White light endoscopy (WLE) and Narrow Band Imaging (NBI) have failed to demonstrate reliable endoscopic signs of carcinoid.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Raj Srirajaskanthan
#2080 Linked Colour Imaging Increases the Diagnostic Yield of Type 1 Gastric Carcinoid
Introduction: Type 1 Gastric carcinoid tumours (GCTs) are the most common neuroendocrine tumours of the stomach. Endoscopic diagnosis of Type 1 GCTs remains a challenge. White light endoscopy (WLE) and Narrow Band Imaging (NBI) have failed to demonstrate reliable endoscopic signs of carcinoid.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Raj Srirajaskanthan
#1890 Natural History of Type 1 Gastric Carcinoid (gNENs) and Risk of Adenoma/Adenocarcinoma in Endoscopic Surveillance Programme
Introduction: Patients with gNENs & autoimmune gastritis are exposed to 2 malignant risks: 1)transformation of gNENs, felt to be low & guidelines advocate either resection of all lesions or selective endoscopic mucosal resection(EMR) of larger lesions; 2)ill-defined risk of gastric adenoma/adenocarcinoma.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD, MRCPI, MRCP Jun Liong Chin
Keywords: Type 1 g-NENs
#375 How Long to Continue Surveillance in Patients Following ‘Curative Resection’ of Primary Small Bowel Tumors?
Introduction: Around 40-50% of patients with small bowel (SB) NETs have metastatic disease at the time of presentation. The majority of the remainder proceed to surgery for attempted curative resection. The optimal duration of surveillance post ‘curative surgical’ resection of primary SB NETs is unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#1514 Number and Localization of Positive Lymph Nodes Correlate with Recurrence in Nonfunctioning Pancreatic Neuroendocrine Neoplasms: Implications for Surgery, Staging and Surveillance
Introduction: Lymph Nodes involvement is a powerful prognostic factor for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PNEN)
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Stefano Partelli
Keywords: PNEN, nodes
#1493 Efficacy and Tolerance of a Simplified Combination of Streptozotocine and Epi-adriamycine in Metastatic Foregut Neuroendocrine Tumor (NET). A Pilot Study
Introduction: Since more than 30 years the combination of Adriamycine (A) and Streptozotocine (STZ) is considered as one of the standard chemotherapy regimens (Moertel et al, N Engl J Med 1992, 326 : 519-23) for patients with aggressive grade 2 metastatic pancreatic NET (PNET).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Celine Lepère
Authors: Hirsch L, Lepère C, Zaanan A, Landi B, ...
#29 Serum chromogranin A correlation with tumor burden in metastatic small bowel carcinoid patients
Introduction: Patients with neuroendocrine tumors may have clinical courses that range from fairly indolent to more aggressive. Cross–sectional studies, nuclear imaging and biochemical markers are often used to monitor disease progression. Optimal surveillance tests and intervals have not been firmly established. Studies suggest that chromogranin A (CgA) may be a surrogate marker for tumor burden.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr. Thomas Curran
#81 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): our experience in a multidisciplinary team in a university hospital
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a low incidence and prevalence representing < 2% of all gastrointestinal tumors with a heterogeneous biological behavior and an often complex management.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Jose Manuel Cabezas-Agricola
#89 Hyperplasia-adenoma sequence in pituitary carcinogenesis: new insight into the role of AIP gene
Introduction: Pituitary adenoma predisposition has been recently associated with germline mutations in the Aryl-Hydrocarbon Receptor Interacting Protein (AIP) gene. This association has been detected in familial and, more rarely, in sporadic cases. The mechanisms by which the AIP mutations promote pituitary adenoma development remain unknown.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MD Chiara Villa